The Gross Law Firm Notifies Shareholders of West Pharmaceutical Services, Inc. (WST) of a Class Action Lawsuit and an Upcoming Deadline

Core Viewpoint - The Gross Law Firm is notifying shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that negatively impacted the company's financial performance during the specified class period [1][3]. Group 1: Allegations - The complaint alleges that West Pharmaceutical Services issued materially false and misleading statements regarding customer demand visibility and attributed operational challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is claimed that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with longstanding customers [3]. - As a result of these factors, the positive statements made by the defendants about the company's business and prospects were materially false or misleading [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 16, 2023, to February 12, 2025, with a deadline for shareholders to register for the class action set for July 7, 2025 [3][4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle, and there is no cost or obligation to participate [4]. - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring responsible business practices by companies [5].